Table 5.

Univariate analysis results of resistance development by patient risk factors and characteristics

Risk factor or characteristicaPb
Age0.16c
Weight0.17c
AUC0–24/MIC ratio<<0.001c
Gender0.77
Infection with:
Pseudomonas spp.0.0002
 Type I β-lac+ organisms0.74
 Other gram-negative rods0.008
 Miscellaneous organisms0.04
Treatment with:
 CIP + PIP0.11
 CAZ0.76
 Cefmenoxime0.01
 CIP0.54
 CAZ + TOB0.29
Ventilator dependent0.91
Major surgery0.24
COPD0.67
Steroids0.82
Diabetes mellitus0.82
Malignancy0.22
Chemotherapy or radiation therapy0.57
Prior antibiotics0.02
Type I β-lac+organisms; β-lactam monotherapy0.001
  • a β-lac+, β-lactamase producing; CIP, ciprofloxacin; PIP, piperacillin; CAZ, ceftazidime; TOB, tobramycin.

  • b As evaluated by the chi-square test.

  • c Determined by Kruskal-Wallis one-way analysis of variance.